

Date: 15 June 2015

Resonance Health partners with CSIRO

The Board of Resonance Health (ASX: RHT) today announced that the Company will collaborate with the Commonwealth Scientific and Industrial Research Organisation (CSIRO) to apply CSIRO expertise in the Company's product development pipeline.

Sander Bangma, General Manager of Resonance Health said "We are delighted at this opportunity to develop a collaborative relationship with one of Australia's leading research organisations. We see this has the potential to turn into a longer-term partnership in research. The initial body of work will be assisting the Company to enhance its MR image analysis software for the measurement of liver fibrosis directly."

The Company will be working together with CSIRO's Biomedical Imaging Group led by Dr Olivier Salvado. The group's wide ranging expertise has the potential to complement the Company's development pipeline. Within the liver fibrosis project CSIRO will use a number of software components and algorithms that are packaged within an image processing and viewing platform, and cloud-based analysis platform. Dr Salvado said "Working with Resonance Health is a perfect partnership to translate our world-class research to the clinic, ultimately benefiting doctors and patients, while supporting successful Australian company leverage its research and development pipeline internationally."

This work has been partially funded by the Research Connections stream from the Department of Industry and Science Entrepreneurs' Infrastructure Programme. The outcomes of this research are expected to become available in Q4 2015.

In conjunction with this piece of work the Company is committed to progressing with the results of its current prototype.

Resonance Health develops and delivers non-invasive image analysis technologies used by clinicians globally for accurate assessment of their patients' conditions. These include FerriScan® for the measurement of liver iron overload and HepaFat-Scan® for the measurement of liver fat. The Company recently announced it has developed a promising prototype for a non-invasive fibrosis measurement that distinguishes between low and high fibrosis scores in a patient cohort with Hepatitis C.

For further information contact:

Sander Bangma

Resonance Health

SanderB@resonancehealth.com

P: +61 (0)8 9286 5300

W: www.resonancehealth.com

Adrian Bowers

Company Secretary

AdrianB@resonancehealth.com

Resonance Health Limited ABN: 96 006 762 492

278 Stirling Hwy, Claremont, WA 6010, AUSTRALIA Postal: PO Box 1135, Nedlands, WA 6909, AUSTRALIA

T: +61 (0) 8 9286 5300 F: +61 (0) 8 9286 1179 www.resonancehealth.com